Rates of, and risk factors for, severe infections in patients with systemic autoimmune diseases receiving biological agents off-label.
about
Current and emerging treatment options in the management of lupusKey issues in the management of patients with systemic lupus erythematosus: latest developments and clinical implicationsSerious infections in patients with rheumatoid arthritis and other immune-mediated connective tissue diseases exposed to anti-TNF or rituximab: data from the Spanish registry BIOBADASER 2.0.Risk factors for severe bacterial infections in patients with systemic autoimmune diseases receiving rituximab.Novel therapeutic agents in clinical development for systemic lupus erythematosus.The risk factors for nosocomial infection in chinese patients with active rheumatoid arthritis in shanghai.Infection and Lupus: Which Causes Which?B Cell in Autoimmune Diseases.B-cell-depleting therapy in systemic lupus erythematosus.Infection risk in systemic lupus erythematosus patients: susceptibility factors and preventive strategies.Vaccines and biologics.Safety of off-label biologicals in systemic lupus erythematosus.Safety issues and concerns of new immunomodulators in rheumatology.Relevance of lymphocyte subsets to B cell-targeted therapy in systemic lupus erythematosus.Progress with the use of monoclonal antibodies for the treatment of systemic lupus erythematosus.Clinical characteristics and risk factors of severe infections in hospitalized adult patients with primary nephrotic syndrome.Infections and systemic lupus erythematosus.Staphylococcus aureus sepsis after etanercept induction in a hemodialysis patient.
P2860
Q26741266-D43F94C1-833F-479F-8A4C-840D61A37647Q26775756-B2F9E80B-BC8C-4E8E-AD38-44357C56598FQ30731527-9C177958-7AEF-4B1C-A48C-1327CB57B1ECQ33757203-192DE71B-71F0-47BE-BA35-1BEDDB15E44AQ34704902-88226888-2AC1-4144-8996-882CBD5E17C5Q35893575-B167D3F3-3E47-4E0F-8A46-3E2F64064553Q35948285-BF7E1F9F-DC24-493A-9A4C-249EAA85B358Q36954468-1063707B-2127-4003-8CE9-BD1FB4C3A556Q37586344-06188397-4913-4ABF-9DAB-FBB78CF937E0Q38149856-F9717433-E88B-4E4C-BA71-4159EA61B4B8Q38213192-05D4CB2A-230B-415B-8F0A-BB464167C7E6Q38284560-082B6146-8396-4003-B43F-62A6476DE5D0Q38292111-33173950-5B08-43E7-8FC7-CF09F6A9D22EQ38306720-CA1A7FEA-13B5-4618-A5D2-71C21731F7D1Q38389307-AAE7936A-53DE-40FD-B841-ED2CDC6CF165Q40153750-CBBDD236-AF10-40B8-A302-2A993F15C352Q42220143-98D3D7EC-D3B8-43AB-ACD7-5BDFA75865A3Q44860740-A6326594-9510-407A-A7E3-785E12D64EDF
P2860
Rates of, and risk factors for, severe infections in patients with systemic autoimmune diseases receiving biological agents off-label.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Rates of, and risk factors for ...... g biological agents off-label.
@ast
Rates of, and risk factors for ...... g biological agents off-label.
@en
type
label
Rates of, and risk factors for ...... g biological agents off-label.
@ast
Rates of, and risk factors for ...... g biological agents off-label.
@en
prefLabel
Rates of, and risk factors for ...... g biological agents off-label.
@ast
Rates of, and risk factors for ...... g biological agents off-label.
@en
P2093
P2860
P50
P356
P1476
Rates of, and risk factors for ...... g biological agents off-label.
@en
P2093
Agustín Martínez-Berriotxoa
Albert Selva-O'Callaghan
BIOGEAS Study Group
Carmen Hidalgo
Cándido Díaz-Lagares
Francisco J García-Hernández
Javier Rascón
Jesús Canora-Lebrato
Joaquim Oristrell
José Luis Callejas
P2860
P2888
P356
10.1186/AR3397
P577
2011-07-11T00:00:00Z
P5875
P6179
1012217984